CJC-1295 without DAC is a synthetic modified analogue of growth hormone-releasing hormone (GHRH), comprising a 29 amino acid sequence with structural modifications that enhance receptor binding affinity. Without the DAC modification, it exhibits a shorter half-life resulting in pulsatile GH release patterns that more closely resemble endogenous secretion in experimental models.
GHRH Receptor Interactions
Preclinical research has examined CJC-1295 No DAC's binding affinity for GHRH receptors in the anterior pituitary and its ability to stimulate growth hormone secretion in experimental models. Studies have documented dose-dependent effects on GH pulse amplitude and frequency in rodent models.
Somatotropic Axis Research
Research has explored the compound's downstream effects on IGF-1 axis modulation in preclinical settings. Studies examining the relationship between pulsatile GH secretion and IGF-1 production have used CJC-1295 No DAC as a research tool to better understand hypothalamic-pituitary-hepatic axis signaling dynamics.
Comparative Half-Life Studies
A notable area of CJC-1295 No DAC research involves comparative pharmacokinetic studies examining the significance of GH release pattern on downstream biological effects in experimental models.
• Ionescu M & Frohman LA (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797.
